Mindy K Ross1, Jinsung Yoon2, Auke van der Schaar3, Mihaela van der Schaar2,4. 1. 1 Department of Pediatrics, Division of Pediatric Pulmonology and Sleep Medicine, and. 2. 2 Department of Electrical Engineering, University of California-Los Angeles, Los Angeles, California. 3. 3 Stratagem Technologies, London, United Kingdom; and. 4. 4 Oxford-Man Institute, University of Oxford, Oxford, United Kingdom.
Abstract
RATIONALE: Pediatric asthma has variable underlying inflammation and symptom control. Approaches to addressing this heterogeneity, such as clustering methods to find phenotypes and predict outcomes, have been investigated. However, clustering based on the relationship between treatment and clinical outcome has not been performed, and machine learning approaches for long-term outcome prediction in pediatric asthma have not been studied in depth. OBJECTIVES: Our objectives were to use our novel machine learning algorithm, predictor pursuit (PP), to discover pediatric asthma phenotypes on the basis of asthma control in response to controller medications, to predict longitudinal asthma control among children with asthma, and to identify features associated with asthma control within each discovered pediatric phenotype. METHODS: We applied PP to the Childhood Asthma Management Program study data (n = 1,019) to discover phenotypes on the basis of asthma control between assigned controller therapy groups (budesonide vs. nedocromil). We confirmed PP's ability to discover phenotypes using the Asthma Clinical Research Network/Childhood Asthma Research and Education network data. We next predicted children's asthma control over time and compared PP's performance with that of traditional prediction methods. Last, we identified clinical features most correlated with asthma control in the discovered phenotypes. RESULTS: Four phenotypes were discovered in both datasets: allergic not obese (A+/O-), obese not allergic (A-/O+), allergic and obese (A+/O+), and not allergic not obese (A-/O-). Of the children with well-controlled asthma in the Childhood Asthma Management Program dataset, we found more nonobese children treated with budesonide than with nedocromil (P = 0.015) and more obese children treated with nedocromil than with budesonide (P = 0.008). Within the obese group, more A+/O+ children's asthma was well controlled with nedocromil than with budesonide (P = 0.022) or with placebo (P = 0.011). The PP algorithm performed significantly better (P < 0.001) than traditional machine learning algorithms for both short- and long-term asthma control prediction. Asthma control and bronchodilator response were the features most predictive of short-term asthma control, regardless of type of controller medication or phenotype. Bronchodilator response and serum eosinophils were the most predictive features of asthma control, regardless of type of controller medication or phenotype. CONCLUSIONS: Advanced statistical machine learning approaches can be powerful tools for discovery of phenotypes based on treatment response and can aid in asthma control prediction in complex medical conditions such as asthma.
RATIONALE: Pediatric asthma has variable underlying inflammation and symptom control. Approaches to addressing this heterogeneity, such as clustering methods to find phenotypes and predict outcomes, have been investigated. However, clustering based on the relationship between treatment and clinical outcome has not been performed, and machine learning approaches for long-term outcome prediction in pediatric asthma have not been studied in depth. OBJECTIVES: Our objectives were to use our novel machine learning algorithm, predictor pursuit (PP), to discover pediatric asthma phenotypes on the basis of asthma control in response to controller medications, to predict longitudinal asthma control among children with asthma, and to identify features associated with asthma control within each discovered pediatric phenotype. METHODS: We applied PP to the Childhood Asthma Management Program study data (n = 1,019) to discover phenotypes on the basis of asthma control between assigned controller therapy groups (budesonide vs. nedocromil). We confirmed PP's ability to discover phenotypes using the Asthma Clinical Research Network/Childhood Asthma Research and Education network data. We next predicted children's asthma control over time and compared PP's performance with that of traditional prediction methods. Last, we identified clinical features most correlated with asthma control in the discovered phenotypes. RESULTS: Four phenotypes were discovered in both datasets: allergic not obese (A+/O-), obese not allergic (A-/O+), allergic and obese (A+/O+), and not allergic not obese (A-/O-). Of the children with well-controlled asthma in the Childhood Asthma Management Program dataset, we found more nonobese children treated with budesonide than with nedocromil (P = 0.015) and more obesechildren treated with nedocromil than with budesonide (P = 0.008). Within the obese group, more A+/O+ children's asthma was well controlled with nedocromil than with budesonide (P = 0.022) or with placebo (P = 0.011). The PP algorithm performed significantly better (P < 0.001) than traditional machine learning algorithms for both short- and long-term asthma control prediction. Asthma control and bronchodilator response were the features most predictive of short-term asthma control, regardless of type of controller medication or phenotype. Bronchodilator response and serum eosinophils were the most predictive features of asthma control, regardless of type of controller medication or phenotype. CONCLUSIONS: Advanced statistical machine learning approaches can be powerful tools for discovery of phenotypes based on treatment response and can aid in asthma control prediction in complex medical conditions such as asthma.
Entities:
Keywords:
allergy; asthma; machine-learning; obesity; personalized medicine
Authors: Hemant P Sharma; Elizabeth C Matsui; Peyton A Eggleston; Nadia N Hansel; Jean Curtin-Brosnan; Gregory B Diette Journal: Pediatrics Date: 2007-11 Impact factor: 7.124
Authors: Loren C Denlinger; Christine A Sorkness; Vernon M Chinchilli; Robert F Lemanske Journal: J Allergy Clin Immunol Date: 2006-12-04 Impact factor: 10.793
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Pranab Haldar; Ian D Pavord; Ruth H Green; Dominic E Shaw; Michael A Berry; Michael Thomas; Christopher E Brightling; Andrew J Wardlaw Journal: Am J Respir Crit Care Med Date: 2008-05-14 Impact factor: 21.405
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Carol A Giffen; Leslie E Carroll; John T Adams; Sean P Brennan; Sean A Coady; Elizabeth L Wagner Journal: Biopreserv Biobank Date: 2015-07-17 Impact factor: 2.300
Authors: Michael Tran Duong; Andreas M Rauschecker; Jeffrey D Rudie; Po-Hao Chen; Tessa S Cook; R Nick Bryan; Suyash Mohan Journal: Br J Radiol Date: 2019-07-26 Impact factor: 3.039
Authors: Akiva Kleinerman; Ariel Rosenfeld; David Benrimoh; Robert Fratila; Caitrin Armstrong; Joseph Mehltretter; Eliyahu Shneider; Amit Yaniv-Rosenfeld; Jordan Karp; Charles F Reynolds; Gustavo Turecki; Adam Kapelner Journal: PLoS One Date: 2021-11-12 Impact factor: 3.240
Authors: Anne M Fitzpatrick; Abby D Mutic; Ahmad F Mohammad; Susan T Stephenson; Jocelyn R Grunwell Journal: J Allergy Clin Immunol Pract Date: 2021-10-22
Authors: Tellen D Bennett; Tiffany J Callahan; James A Feinstein; Debashis Ghosh; Saquib A Lakhani; Michael C Spaeder; Stanley J Szefler; Michael G Kahn Journal: J Pediatr Date: 2019-01-25 Impact factor: 4.406
Authors: Tesfaye B Mersha; Yashira Afanador; Elisabet Johansson; Steven P Proper; Jonathan A Bernstein; Marc E Rothenberg; Gurjit K Khurana Hershey Journal: Clin Rev Allergy Immunol Date: 2021-04 Impact factor: 8.667